Evidence map›Paper›PMID 29258557›Full record

ArticleRetrovirology2017

Moloney leukemia virus 10 (MOV10) inhibits the degradation of APOBEC3G through interference with the Vif-mediated ubiquitin-proteasome pathway.

Cancan Chen, Xiaocao Ma, Qifei Hu, Xinghua Li, Feng Huang, Junsong Zhang, Ting Pan, Jinyu Xia, Chao Liu, Hui Zhang

Open access · goldAbstract read
In one paragraph

Article in Retrovirology, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 12 papers.

0numbers the graph read from it
0cells of the map it votes in
12citing papers in PubMed
1.5field-weighted citation impact, top 19% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

12 citing papers in PubMed, 15 citations in OpenAlex.

  1. Article
  2. Article
  3. Review
  4. Unwinding the roles of RNA helicase MOV10.Wiley interdisciplinary reviews. RNA · 2022
    Review
  5. Article
  6. Review
  7. Roles of MOV10 in Animal RNA Virus Infection.Frontiers in veterinary science · 2020
    Review
  8. Article
  9. Article
  10. Review
  11. Article
  12. Strategies for Success. Viral Infections and Membraneless Organelles.Frontiers in cellular and infection microbiology · 2019
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Cancan ChenInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xiaocao MaInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Qifei HuInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Xinghua LiDepartment of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, China.
Feng HuangInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Junsong ZhangInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Ting PanInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Jinyu XiaDepartment of Infectious Diseases, The Fifth Affiliated Hospital, Sun Yat-sen University, Zhuhai, 519000, China.
Chao LiuInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China. liuchao9@mail.sysu.edu.cn.ORCID http://orcid.org/0000-0003-3863-7210
Hui ZhangInstitute of Human Virology, Zhongshan School of Medicine, Sun Yat-sen University, Guangzhou, 510080, China.
Sun Yat-sen University · CN

Funding

Important Key Program of Natural Science Foundation of China No. 81590765Introduction of Innovative R&D Team Program of Guangdong Province No. 2009010058Joint-innovation Program in Healthcare for Special Scientific Research Projects of Guangzhou, China No. 201508020256National Natural Science Foundation of China No. 81471935National Natural Science Foundation of China (NSFC-NIH project) No. 81561128007
6 · The paper itself

Abstract

backgroundMOV10 protein has ATP-dependent 5'-3' RNA helicase activity and belongs to the UPF1p superfamily. It can inhibit human immunodeficiency virus type 1 (HIV-1) replication at multiple stages and interact with apolipoprotein-B-mRNA-editing enzyme catalytic polypeptide-like 3G (APOBEC3G or A3G), a member of the cytidine deaminase family that exerts potent inhibitory effects against HIV-1 infection. However, HIV-1-encoded virion infectivity factor (Vif) protein specifically mediates the degradation of A3G via the ubiquitin-proteasome system (UPS).

resultsWe demonstrate that MOV10 counteracts Vif-mediated degradation of A3G by inhibiting the assembly of the Vif-CBF-β-Cullin 5-ElonginB-ElonginC complex. Through interference with UPS, MOV10 enhances the level of A3G in HIV-1-infected cells and virions, and synergistically inhibits the replication and infectivity of HIV-1. In addition, the DEAG-box of MOV10 is required for inhibition of Vif-mediated A3G degradation as the DEAG-box mutant significantly loses this ability.

conclusionsOur results demonstrate a novel mechanism involved in the anti-HIV-1 function of MOV10. Given that both MOV10 and A3G belong to the interferon antiviral system, their synergistic inhibition of HIV-1 suggests that these proteins may play complicated roles in antiviral functions.

Indexed as

Antiviral AgentsAPOBEC-3G DeaminaseCell Line, TransformedHEK293 CellsHIV InfectionsHost-Pathogen InteractionsHumansMutationProteasome Endopeptidase ComplexRNA HelicasesSignal TransductionUbiquitinvif Gene Products, Human Immunodeficiency VirusVirus ReplicationAntiviral AgentsAPOBEC-3G DeaminaseAPOBEC3G protein, humanMov10 protein, humanProteasome Endopeptidase ComplexRNA HelicasesUbiquitinvif Gene Products, Human Immunodeficiency VirusA3GHIV-1MOV10Ubiquitin–proteasome system (UPS)Vif

Identifiers

PMID29258557
PMCPMC5735797
OpenAlexW2780252963

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.